What this site is
GetRetatrutide.ca is an educational resource that provides evidence-based information about retatrutide (LY3437943) — an investigational triple-agonist weight loss treatment in Phase 3 clinical trials. We track clinical data, trial progress, access pathways, and safety information.
What this site is not
- Not a pharmacy, clinic, or medical practice
- Not affiliated with Eli Lilly or any pharmaceutical company
- Not a seller or facilitator of any medication
- Not a substitute for professional medical advice
- Not a source for purchasing retatrutide or any other drug
Our approach
We source information from:
- Published peer-reviewed clinical trial results (NEJM, Lancet, etc.)
- ClinicalTrials.gov registry data
- Health Canada and FDA regulatory information
- Eli Lilly press releases and investor communications
- Medical conference presentations and abstracts
We aim to present information clearly and accurately, distinguishing between established facts, clinical trial data (with appropriate caveats), and areas where evidence is still emerging. Cross-trial comparisons are always accompanied by appropriate cautions.
Editorial independence: This site is not sponsored, funded, or influenced by any pharmaceutical company. We do not accept payment for content, referrals, or placement.